Femasys (NASDAQ:FEMY) Releases Earnings Results, Beats Expectations By $0.07 EPS

Femasys (NASDAQ:FEMY) released its earnings results on Friday. The company reported $0.00 EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.07, reports. The business had revenue of $0.42 million during the quarter, compared to analysts’ expectations of $0.77 million. Femasys had a negative net margin of 812.74% and a negative return on equity of 534.94%.

Femasys Price Performance

NASDAQ FEMY traded down $0.02 during trading hours on Friday, hitting $0.43. 524,290 shares of the company’s stock traded hands, compared to its average volume of 412,557. Femasys has a 52-week low of $0.31 and a 52-week high of $1.14. The company has a market capitalization of $25.96 million, a PE ratio of -0.86 and a beta of -2.26. The company has a debt-to-equity ratio of 0.89, a current ratio of 4.53 and a quick ratio of 2.95. The firm’s 50-day moving average is $0.47 and its 200-day moving average is $0.62.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Wall Street Zen cut shares of Femasys from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Lake Street Capital assumed coverage on shares of Femasys in a research note on Tuesday, March 3rd. They set a “buy” rating and a $1.50 target price for the company. Finally, Weiss Ratings raised shares of Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $5.50.

Institutional Trading of Femasys

Several large investors have recently bought and sold shares of the business. Cetera Investment Advisers purchased a new stake in Femasys during the 4th quarter valued at about $36,000. Kovack Advisors Inc. purchased a new stake in Femasys during the 4th quarter valued at about $27,000. State Street Corp grew its stake in Femasys by 43.5% during the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after acquiring an additional 24,500 shares in the last quarter. Jane Street Group LLC purchased a new stake in Femasys during the 4th quarter valued at about $62,000. Finally, HRT Financial LP purchased a new stake in Femasys during the 4th quarter valued at about $30,000. Hedge funds and other institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.